Efficacy, safety of biosimilar filgrastim similar to that of filgrastim in daily practice
the ONA take:
The clinical effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim for the prevention of chemotherapy-induced (febrile) neutropenia, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the international, prospective, observational, open-label MONITOR-GCSF study, researchers enrolled 1,447 patients with cancer treated with myelosuppressive chemotherapy and receiving prophylaxis with biosimilar filgrastim. Of those, 72.3% received primary prophylaxis and 53.2% initiated prophylaxis between 24 and 72 hours after chemotherapy.
Results showed that 13.2% and 5.9% of patients experienced grade 4 chemotherapy-induced neutropenia and febrile neutropenia, respectively.
Researchers found that 6.1% of patients were hospitalized for (febrile) neutropenia. In regard to safety, 24.7% of patients reported any grade bone pain and 76 patients experienced a total of 148 adverse drug events, of which 4 were serious.
Effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- ONS Partners with ASCO CancerLinQ to Launch CancerLinQ® Ambassadors Program
- Characteristics of Clinical Trials and Barriers to Patient Enrollment Identified
- Exercise Improves Coping While Undergoing Chemotherapy for Advanced GI Cancer
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|